{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04984343",
            "orgStudyIdInfo": {
                "id": "21-02023315"
            },
            "organization": {
                "fullName": "Weill Medical College of Cornell University",
                "class": "OTHER"
            },
            "briefTitle": "Randomized Trial of Five or Two MRI-Guided Adaptive Radiotherapy Treatments for Prostate Cancer",
            "officialTitle": "Randomized Phase II Trial of Five or Two MRI-Guided Adaptive Radiotherapy Treatments for Prostate Cancer",
            "acronym": "FORT",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "randomized-trial-of-five-or-two-mri-guided-adaptive-radiotherapy-treatments-for-prostate-cancer"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-02-11",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-12-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-12-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-07-29",
            "studyFirstSubmitQcDate": "2021-07-29",
            "studyFirstPostDateStruct": {
                "date": "2021-07-30",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-25",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-26",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Weill Medical College of Cornell University",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "Viewray Inc.",
                    "class": "INDUSTRY"
                },
                {
                    "name": "Progenics Pharmaceuticals, Inc.",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": true,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "The study is a randomized study that compares 5 radiation therapy treatments to 2 radiation therapy treatments in men with low or intermediate-risk prostate cancer.",
            "detailedDescription": "This study is a randomized non-inferiority trial comparing 5 to 2 radiotherapy treatments using an MRI linear accelerator for men with low or intermediate-risk prostate cancer electing for definitive radiotherapy."
        },
        "conditionsModule": {
            "conditions": [
                "Prostate Cancer"
            ],
            "keywords": [
                "Low or intermediate risk prostate cancer",
                "Definitive radiotherapy",
                "MRI Linear accelerator"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 136,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "5 radiation treatments - ARM 1",
                    "type": "EXPERIMENTAL",
                    "description": "Patients randomized to ARM 1 will receive 37.5 in 5 radiotherapy treatments.",
                    "interventionNames": [
                        "Radiation: Radiation Therapy"
                    ]
                },
                {
                    "label": "2 radiation treatments - ARM 2",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Patients randomized to ARM 2 will receive 25 Gy in 2 radiotherapy treatments.",
                    "interventionNames": [
                        "Radiation: Radiation Therapy"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "RADIATION",
                    "name": "Radiation Therapy",
                    "description": "Eligible subjects will be randomly assigned to 5 or 2 fraction treatment groups in a 1:1 ratio using a computer-generated randomization scheme.\n\nAfter consent and eligibility verification, patients will undergo CT/MRI simulation and radiotherapy planning. Patients will receive treatment to the prostate +/- seminal vesicles per treating physician's discretion in either 37.5 Gy in 5 fractions or 25 Gy in 2 fractions. SIB use is at treating physician's discretion and should be concordant with imaging and biopsy findings with no PTV expansion.\n\nSubjects on 5 fraction arm should be treated on non-consecutive days. Subjects on the 2 fraction arm must have \\>72 hours between beginning of each fraction.",
                    "armGroupLabels": [
                        "2 radiation treatments - ARM 2",
                        "5 radiation treatments - ARM 1"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Change in the number of patient-reported GI symptoms using the Expanded Prostate Cancer Index Composite (EPIC)",
                    "description": "The primary objective is to demonstrate that 2 treatments of radiotherapy does not significantly increase patient-reported Gastrointestinal (GI) and Genitourinary (GU) symptoms compared to 5 treatments of radiotherapy 2 years after treatment completion.",
                    "timeFrame": "Baseline, 24 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Change in the number of patient reported GI symptoms at specific intervals as measured by Expanded Prostate Cancer Index Composite (EPIC)",
                    "description": "Compare patient-reported GI symptoms using the EPIC at end of RT and 3, 6, 12, and 60 months from end of treatment.\n\nExpanded Prostate Cancer Index Composite (EPIC) short form questionnaire. The Expanded Prostate Cancer Index Composite (EPIC) is a comprehensive instrument designed to evaluate patient function and bother after prostate cancer treatment. Scores range from 0 to 100, lower scores indicate worse outcomes and higher EPIC scores represent better outcomes.\n\nAdverse events can be unexpected or expected, related to treatment.",
                    "timeFrame": "Baseline, 1 week , 3months, 6 months, 12 months and 60 months"
                },
                {
                    "measure": "Change in the number of patient reported GU symptoms at specific intervals as measured by Expanded Prostate Cancer Index Composite (EPIC)",
                    "description": "Compare patient-reported GU symptoms using the EPIC at end of RT and 3, 6, 12, and 60 months from end of treatment.\n\nExpanded Prostate Cancer Index Composite (EPIC) short form questionnaire. The Expanded Prostate Cancer Index Composite (EPIC) is a comprehensive instrument designed to evaluate patient function and bother after prostate cancer treatment. Scores range from 0 to 100, lower scores indicate worse outcomes and higher EPIC scores represent better outcomes.\n\nAdverse events can be unexpected or expected, related to treatment.",
                    "timeFrame": "Baseline, 1 week, 3months, 6 months, 12 months and 60 months"
                },
                {
                    "measure": "Change in the number of patient reported sexual symptoms at specific intervals as measured by Expanded Prostate Cancer Index Composite (EPIC)",
                    "description": "Compare patient-reported sexual symptoms using the EPIC at end of RT and 3, 6, 12, 24, and 60 months from end of treatment.\n\nExpanded Prostate Cancer Index Composite (EPIC) short form questionnaire. The Expanded Prostate Cancer Index Composite (EPIC) is a comprehensive instrument designed to evaluate patient function and bother after prostate cancer treatment. Scores range from 0 to 100, lower scores indicate worse outcomes and higher EPIC scores represent better outcomes.\n\nAdverse events can be unexpected or expected, related to treatment.",
                    "timeFrame": "Baseline, 1 week, 3months, 6 months, 12 months and 60 months"
                },
                {
                    "measure": "Time to Progression (TTP)",
                    "description": "Compare time to progression (TTP) where progression is defined as the first occurrence of biochemical failure (BF), local failure, regional failure, distant metastasis (DM), institution of new unplanned anticancer treatment, or death from prostate cancer (PCSM).",
                    "timeFrame": "3 months"
                },
                {
                    "measure": "Time to Progression (TTP)",
                    "description": "Compare time to progression (TTP) where progression is defined as the first occurrence of biochemical failure (BF), local failure, regional failure, distant metastasis (DM), institution of new unplanned anticancer treatment, or death from prostate cancer (PCSM).",
                    "timeFrame": "6 months"
                },
                {
                    "measure": "Time to Progression (TTP)",
                    "description": "Compare time to progression (TTP) where progression is defined as the first occurrence of biochemical failure (BF), local failure, regional failure, distant metastasis (DM), institution of new unplanned anticancer treatment, or death from prostate cancer (PCSM).",
                    "timeFrame": "12 months"
                },
                {
                    "measure": "Time to Progression (TTP)",
                    "description": "Compare time to progression (TTP) where progression is defined as the first occurrence of biochemical failure (BF), local failure, regional failure, distant metastasis (DM), institution of new unplanned anticancer treatment, or death from prostate cancer (PCSM).",
                    "timeFrame": "60 months"
                },
                {
                    "measure": "Compare Overall Survival Rates",
                    "description": "Compare Overall Survival (OS) in patients among the two arms, 37.5 Gy in 5 fractions and 25 Gy in 2 fractions.",
                    "timeFrame": "3 months"
                },
                {
                    "measure": "Compare Overall Survival Rates",
                    "description": "Compare Overall Survival (OS) in patients among the two arms, 37.5 Gy in 5 fractions and 25 Gy in 2 fractions.",
                    "timeFrame": "6 months"
                },
                {
                    "measure": "Compare Overall Survival Rates",
                    "description": "Compare Overall Survival (OS) in patients among the two arms, 37.5 Gy in 5 fractions and 25 Gy in 2 fractions.",
                    "timeFrame": "12 months"
                },
                {
                    "measure": "Compare Overall Survival Rates",
                    "description": "Compare Overall Survival (OS) in patients among the two arms, 37.5 Gy in 5 fractions and 25 Gy in 2 fractions.",
                    "timeFrame": "60 months"
                },
                {
                    "measure": "prostate cancer specific survival",
                    "description": "compare prostate cancer specific survival in patients among the two arms, 37.5 Gy in 5 fractions and 25 Gy in 2 fractions.",
                    "timeFrame": "3 months"
                },
                {
                    "measure": "prostate cancer specific survival",
                    "description": "compare prostate cancer specific survival in patients among the two arms, 37.5 Gy in 5 fractions and 25 Gy in 2 fractions.",
                    "timeFrame": "6 months"
                },
                {
                    "measure": "prostate cancer specific survival",
                    "description": "compare prostate cancer specific survival in patients among the two arms, 37.5 Gy in 5 fractions and 25 Gy in 2 fractions.",
                    "timeFrame": "12 months"
                },
                {
                    "measure": "prostate cancer specific survival",
                    "description": "compare prostate cancer specific survival in patients among the two arms, 37.5 Gy in 5 fractions and 25 Gy in 2 fractions.",
                    "timeFrame": "60 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Men aged \\>=18 with histologically confirmed low or intermediate risk prostate cancer per NCCN guidelines.\n* ECOG 0 - 1\n* IPSS \\< 18\n* Ability to receive MRI-guided radiotherapy.\n* Ability to complete the Expanded Prostate Cancer Index Composite (EPIC) questionnaire.\n* Patients with a prior or concurrent disease whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial. Note: Any patient with a cancer (other than keratinocyte carcinoma or carcinoma in situ or low-grade non-muscle invasive bladder cancer) who has been disease-free for less than 3 years must contact the Principal Investigator.\n\nExclusion Criteria:\n\n* Prior history of receiving pelvic radiotherapy.\n* Patient with history of inflammatory bowel disease.\n* MRI Prostate Volume \\> 80 cc\n* MRI Stage \\> T3a\n* Unilateral or bilateral hip replacements.\n* History of bladder neck or urethral stricture.\n* TURP \\< 8 weeks prior to radiotherapy\n* Metastatic (pelvic nodal or distant) disease on CT, Bone, Fluciclovine, and/or PSMA PET scan",
            "healthyVolunteers": false,
            "sex": "MALE",
            "minimumAge": "18 Years",
            "maximumAge": "90 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Sharanya Chandrasekhar",
                    "role": "CONTACT",
                    "phone": "6469623110",
                    "email": "shc2043@med.cornell.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Himanshu Nagar, M.D.",
                    "affiliation": "Weill Medical College of Cornell University",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Weill Cornell Medicine",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10065",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Sharanya Chandrasekhar",
                            "role": "CONTACT",
                            "phone": "646-962-3110",
                            "email": "shc2043@med.cornell.edu"
                        },
                        {
                            "name": "Himanshu Nagar, M.D.",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Genesis Care",
                    "status": "RECRUITING",
                    "city": "Oxford",
                    "zip": "OX4 6LB",
                    "country": "United Kingdom",
                    "contacts": [
                        {
                            "name": "Rabia Bhatti",
                            "role": "CONTACT",
                            "email": "Rabia.Bhatti@genesiscare.co.uk"
                        },
                        {
                            "name": "Philip Camilleri, M.D.",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 51.75222,
                        "lon": -1.25596
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000011471",
                    "term": "Prostatic Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000005834",
                    "term": "Genital Neoplasms, Male"
                },
                {
                    "id": "D000014565",
                    "term": "Urogenital Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000005832",
                    "term": "Genital Diseases, Male"
                },
                {
                    "id": "D000091662",
                    "term": "Genital Diseases"
                },
                {
                    "id": "D000091642",
                    "term": "Urogenital Diseases"
                },
                {
                    "id": "D000011469",
                    "term": "Prostatic Diseases"
                },
                {
                    "id": "D000052801",
                    "term": "Male Urogenital Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M14335",
                    "name": "Prostatic Neoplasms",
                    "asFound": "Prostate Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M8946",
                    "name": "Genital Neoplasms, Male",
                    "relevance": "LOW"
                },
                {
                    "id": "M17315",
                    "name": "Urogenital Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M2876",
                    "name": "Genital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8944",
                    "name": "Genital Diseases, Male",
                    "relevance": "LOW"
                },
                {
                    "id": "M2875",
                    "name": "Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14333",
                    "name": "Prostatic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27095",
                    "name": "Male Urogenital Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        }
    },
    "hasResults": false
}